ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 53 citations in OpenAlex.
- Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020Trial
- Pseudomonas turns protection into pathology.Nature microbiology · 2026Article
- INVICTUS II: comparison of disc diffusion and broth microdilution methods for susceptibility testing of ceftolozane/tazobactam and five comparator agents against a subset of INVICTUS IJAC-antimicrobial resistance · 2026Article
- Variable phage susceptibility ofbioRxiv : the preprint server for biology · 2026Article
- Antibiotic exposure and recovery of persister states influence virulence phenotypes in Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- R pyocin sensitivity ofJournal of medical microbiology · 2026Article
- The Role of the SOS Response in the Adaptation ofCurrent issues in molecular biology · 2026Review
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Inhibition of <italic>Pseudomonas aeruginosa</italic> Biofilm Formation by Peptidyl-Arginine Deiminases 2 and 4.Journal of innate immunity · 2026Article
- Time-resolved dual transcriptomics ofBiofilm · 2025Article
- D-Amino acids affect Pseudomonas aeruginosa biofilm and quorum sensing molecules in lung infection models developed under a cystic fibrosis environment.Scientific reports · 2025Article
- Chronic Airway Infection and Resistance Pattern in Children and Adults with Cystic Fibrosis in Oman: A Single-center Cross-sectional Study.Oman medical journal · 2025Article
- Difficult-to-TreatAntibiotics (Basel, Switzerland) · 2025Review
- Impairing protein-protein interactions in an essential tRNA modification complex: An innovative antimicrobial strategy against Pseudomonas aeruginosa.Journal of peptide science : an official publication of the European Peptide Society · 2025Article
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Clinical epidemiology and impact of Haemophilus influenzae airway infections in adults with cystic fibrosis.BMC infectious diseases · 2024Article
- Preclinical testing of antimicrobials for cystic fibrosis lung infections: current needs and future priorities.Microbiology (Reading, England) · 2023Article
- Novel therapeutic approach for the treatment of cystic fibrosis based on freeze-dried tridrug microparticles to treat cystic fibrosis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023Article
- A Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage againstAntibiotics (Basel, Switzerland) · 2023Article
- Effect of Micro-Patterned Mucin on Quinolone and Rhamnolipid Profiles of MucoidACS infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Background: Chronic Pseudomonas aeruginosa lung infection is associated with significant morbidity and mortality in cystic fibrosis (CF). It is not known whether recent advances in care have affected the rates of chronic infection. We aimed to determine if the rates of developing new chronic P. aeruginosa infection among adolescents and adults with CF significantly changed over time. Methods: The cohort consisted of individuals with CF followed in the Cystic Fibrosis Foundation Patient Registry aged ≥13 years without chronic P. aeruginosa at baseline. Multivariable regression models accounting for within-patient correlation were used to assess the change in rate of developing chronic P. aeruginosa infection between 2003 and 2012. Results: A total of 15504 individuals were followed for a median of 5 (interquartile range, 2-9) years. The annual rates of developing new chronic P. aeruginosa decreased from 14.3% in 2003 to 6.4% in 2012. After adjusting for potential confounders, relative risk (RR) of developing chronic P. aeruginosa infection decreased significantly over time compared to 2003 (P value test of trend < .001). Compared with 2003, the RR of developing chronic P. aeruginosa infection in 2012 was 0.33 (95% confidence interval, 0.30-0.37). No significant increases in risk of chronic infections with other major CF bacterial pathogens relative to 2003 were identified. Conclusions: Among individuals with CF, a significant decrease in the risk and rates of developing chronic P. aeruginosa infection between 2003 and 2012 was observed. Whether this decline results in changes in clinical outcomes warrants further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.